REFERENCES
1. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol 2022;76:1109-21.
2. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
3. Javle M, Lee S, Azad NS, et al. Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017. Oncologist 2022;27:874-83.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;8:512-22.
5. Farshidfar F, Zheng S, Gingras MC, et al; Cancer Genome Atlas Network. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;19:2878-80.
6. Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27.
8. Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50.
9. Patel TH, Marcus L, Horiba MN, et al. FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin Cancer Res 2023;29:838-42.
10. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6:803-15.
11. Gomes DA, Rodrigues MA, Leite MF, et al. C-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem 2008;283:4344-51.
12. de Miranda MC, Rodrigues MA, de Angelis Campos AC, et al. Epidermal growth factor (EGF) triggers nuclear calcium signaling through the intranuclear phospholipase Cδ-4 (PLCδ4). J Biol Chem 2019;294:16650-62.
13. Rodrigues MA, Gomes DA, Leite MF, et al. Nucleoplasmic calcium is required for cell proliferation. J Biol Chem 2007;282:17061-8.
14. Parys JB, Bultynck G, Vervliet T. IP3 receptor biology and endoplasmic reticulum calcium dynamics in cancer. Prog Mol Subcell Biol 2021;59:215-237.
15. Ueasilamongkol P, Khamphaya T, Guerra MT, et al. Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma. Hepatology 2020;71:583-99.
16. Prole DL, Taylor CW. Structure and function of IP3 receptors. Cold Spring Harb Perspect Biol 2019;11:a035063.
17. Tu H, Wang Z, Nosyreva E, De Smedt H, Bezprozvanny I. Functional characterization of mammalian inositol 1,4,5-trisphosphate receptor isoforms. Biophys J 2005;88:1046-55.
18. Hagar RE, Burgstahler AD, Nathanson MH, Ehrlich BE. Type III InsP3 receptor channel stays open in the presence of increased calcium. Nature 1998;396:81-4.
19. Tu H, Wang Z, Bezprozvanny I. Modulation of mammalian inositol 1,4,5-trisphosphate receptor isoforms by calcium: a role of calcium sensor region. Biophys J 2005;88:1056-69.
20. Hirata K, Pusl T, O’Neill AF, Dranoff JA, Nathanson MH. The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes. Gastroenterology 2002;122:1088-100.
21. Cruz LN, Guerra MT, Kruglov E, et al. Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liver. Hepatology 2010;52:327-37.
22. Feriod CN, Oliveira AG, Guerra MT, et al. Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver. Hepatol Commun 2017;1:23-35.
23. Hirata K, Dufour JF, Shibao K, et al. Regulation of Ca2+ signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology 2002;36:284-96.
24. Teos LY, Zhang Y, Cotrim AP, et al. IP3R deficit underlies loss of salivary fluid secretion in Sjögren’s syndrome. Sci Rep 2015;5:13953.
25. Minagawa N, Nagata J, Shibao K, et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007;133:1592-602.
26. Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003;125:1175-87.
27. White C, Li C, Yang J, et al. The endoplasmic reticulum gateway to apoptosis by Bcl-XL modulation of the InsP3R. Nat Cell Biol 2005;7:1021-8.
28. Jouaville LS, Pinton P, Bastianutto C, Rutter GA, Rizzuto R. Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc Natl Acad Sci USA 1999;96:13807-12.
29. Thompson M, Andrade VA, Andrade SJ, et al. Inhibition of the TEF/TEAD transcription factor activity by nuclear calcium and distinct kinase pathways. Biochem Biophys Res Commun 2003;301:267-74.
30. Pusl T, Wu JJ, Zimmerman TL, et al. Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium. J Biol Chem 2002;277:27517-27.
31. Bading H. Nuclear calcium signalling in the regulation of brain function. Nat Rev Neurosci 2013;14:593-608.
32. Khamphaya T, Chukijrungroat N, Saengsirisuwan V, et al. Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor. Hepatology 2018;67:560-74.
33. Amaya MJ, Oliveira AG, Guimarães ES, et al. The insulin receptor translocates to the nucleus to regulate cell proliferation in liver. Hepatology 2014;59:274-83.
34. Guerra MT, Nathanson MH. Calcium signaling and secretion in cholangiocytes. Pancreatology 2015;15:S44-8.
35. Franca A, Carlos Melo Lima Filho A, Guerra MT, et al. Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes. Hepatology 2019;69:817-30.
36. Takeuchi M, Vidigal PT, Guerra MT, et al. Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. Gut 2021;70:342-56.
37. Ananthanarayanan M, Banales JM, Guerra MT, et al. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. J Biol Chem 2015;290:184-96.
38. Weerachayaphorn J, Amaya MJ, Spirli C, et al. Nuclear factor, erythroid 2-like 2 regulates expression of type 3 inositol 1,4,5-trisphosphate receptor and calcium signaling in cholangiocytes. Gastroenterology 2015;149:211-222.e10.
39. Sassano ML, Felipe-Abrio B, Agostinis P. ER-mitochondria contact sites; a multifaceted factory for Ca2+ signaling and lipid transport. Front Cell Dev Biol 2022;10:988014.
40. Lemos FO, França A, Lima Filho ACM, et al. Molecular mechanism for protection against liver failure in human yellow fever infection. Hepatol Commun 2020;4:657-69.
41. Guerra MT, Florentino RM, Franca A, et al. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019;68:1676-87.
42. Lima Filho ACM, França A, Florentino RM, et al. Inositol 1,4,5-trisphosphate receptor type 3 plays a protective role in hepatocytes during hepatic ischemia-reperfusion injury. Cell Calcium 2020;91:102264.
43. Rodrigues MA, Gomes DA, Nathanson MH. Calcium signaling in cholangiocytes: methods, mechanisms, and effects. Int J Mol Sci 2018;19:3913.
44. Mangla A, Guerra MT, Nathanson MH. Type 3 inositol 1,4,5-trisphosphate receptor: a calcium channel for all seasons. Cell Calcium 2020;85:102132.
45. Jin C, Kumar P, Gracia-Sancho J, Dufour JF. Calcium transfer between endoplasmic reticulum and mitochondria in liver diseases. FEBS Lett 2021;595:1411-21.
46. De Stefani D, Rizzuto R, Pozzan T. Enjoy the trip: calcium in mitochondria back and forth. Annu Rev Biochem 2016;85:161-92.
47. Perry RJ, Zhang D, Guerra MT, et al. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. Nature 2020;579:279-83.
48. Rodrigues MA, Gomes DA, Cosme AL, et al. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomed Pharmacother 2022;145:112403.
49. Szabadkai G, Bianchi K, Várnai P, et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 2006;175:901-11.
50. Denton RM, Randle PJ, Martin BR. Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J 1972;128:161-3.
51. Rutter GA, Denton RM. Regulation of NAD+-linked isocitrate dehydrogenase and 2-oxoglutarate dehydrogenase by Ca2+ ions within toluene-permeabilized rat heart mitochondria. Interactions with regulation by adenine nucleotides and NADH/NAD+ ratios. Biochem J 1988;252:181-9.
52. Minagawa N, Kruglov EA, Dranoff JA, et al. The anti-apoptotic protein MCL-1 inhibits mitochondrial Ca2+ signals. J Biol Chem 2005;280:33637-44.
53. Mendes CC, Gomes DA, Thompson M, et al. The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca2+ signals into mitochondria. J Biol Chem 2005;280:40892-900.
54. Guerra MT, Fonseca EA, Melo FM, et al. Mitochondrial calcium regulates rat liver regeneration through the modulation of apoptosis. Hepatology 2011;54:296-306.
55. Cárdenas C, Müller M, McNeal A, et al. Selective vulnerability of cancer cells by inhibition of Ca2+ transfer from endoplasmic reticulum to mitochondria. Cell Rep 2016;14:2313-24.
56. Rosa N, Speelman-Rooms F, Parys JB, Bultynck G. Modulation of Ca2+ signaling by antiapoptotic BCL-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival. Biochim Biophys Acta Rev Cancer 2022;1877:188791.
57. Hoffmeister-Wittmann P, Mock A, Nichetti F, et al. Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma. Liver Int 2022;42:2855-70.
58. Sood A, Jeyaraju DV, Prudent J, et al. A Mitofusin-2-dependent inactivating cleavage of Opa1 links changes in mitochondria cristae and ER contacts in the postprandial liver. Proc Natl Acad Sci USA 2014;111:16017-22.
59. Parlakgül G, Arruda AP, Pang S, et al. Regulation of liver subcellular architecture controls metabolic homeostasis. Nature 2022;603:736-42.
60. Thoudam T, Chanda D, Lee JY, et al. Enhanced Ca2+-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver disease. Nat Commun 2023;14:1703.
61. Guerra MT, Nathanson MH. Above the legal limit: alcohol brings ER and mitochondria too close together. Cell Calcium 2023;113:102763.
62. Tubbs E, Theurey P, Vial G, et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. Diabetes 2014;63:3279-94.
63. Tubbs E, Chanon S, Robert M, et al. Disruption of mitochondria-associated endoplasmic reticulum membrane (MAM) integrity contributes to muscle insulin resistance in mice and humans. Diabetes 2018;67:636-50.
64. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131:596-610.
65. Xu D, Yi W, Chen Y, et al. Overexpression of sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma. Med Oncol 2014;31:261.
66. Koulen P, Cai Y, Geng L, et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002;4:191-7.
67. Kuo IY, Brill AL, Lemos FO, et al. Polycystin 2 regulates mitochondrial Ca2+ signaling, bioenergetics, and dynamics through mitofusin 2. Sci Signal 2019;12:eaat7397.
68. Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep 2021;3:100251.
69. Li Y, Wright JM, Qian F, Germino GG, Guggino WB. Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+signaling. J Biol Chem 2005;280:41298-306.
70. Naon D, Zaninello M, Giacomello M, et al. Critical reappraisal confirms that mitofusin 2 is an endoplasmic reticulum-mitochondria tether. Proc Natl Acad Sci USA 2016;113:11249-54.
71. Rehman J, Zhang HJ, Toth PT, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 2012;26:2175-86.
72. Arruda AP, Pers BM, Parlakgül G, et al. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat Med 2014;20:1427-35.
73. Simmen T, Aslan JE, Blagoveshchenskaya AD, et al. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J 2005;24:717-29.
74. Teng Y, Ren X, Li H, et al. Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein. Oncogene 2016;35:333-43.
75. Parys JB, Vervliet T. New insights in the IP3 receptor and its regulation. Adv Exp Med Biol 2020;1131:243-270.
76. Yang S, Zhou R, Zhang C, He S, Su Z. Mitochondria-associated endoplasmic reticulum membranes in the pathogenesis of type 2 diabetes mellitus. Front Cell Dev Biol 2020;8:571554.
77. Giacomello M, Pellegrini L. The coming of age of the mitochondria-ER contact: a matter of thickness. Cell Death Differ 2016;23:1417-27.
78. Wojcikiewicz RJ, Ernst SA, Yule DI. Secretagogues cause ubiquitination and down-regulation of inositol 1,4,5-trisphosphate receptors in rat pancreatic acinar cells. Gastroenterology 1999;116:1194-201.
79. Chandrasekhar R, Alzayady KJ, Wagner LE 2nd, Yule DI. Unique regulatory properties of heterotetrameric inositol 1,4,5-trisphosphate receptors revealed by studying concatenated receptor constructs. J Biol Chem 2016;291:4846-60.
80. Kodama K, Kawaoka T, Kosaka M, et al. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection. J Gastroenterol 2022;57:676-83.
